64
Participants
Start Date
August 8, 2022
Primary Completion Date
October 31, 2030
Study Completion Date
October 31, 2030
Vaccine
Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
RECRUITING
Levine Cancer Institute, Charlotte
Atrium Health Levine Cancer Institute
OTHER
Wake Forest University Health Sciences
OTHER